This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kissling, W. Articles by Llorca, P. M. Search for Related Content PubMed PubMed Citation Articles by Kissling, W. Articles by Llorca, P. M. Social Bookmarking                   What's this?

Direct transition to long-acting risperidone - analysis of long-term efficacy

Klinikum rechts der Isar, Klinik und Poliklinik für Psychiatrie und Psychotherapie, München, Germany, W.Kissling{at}lrz.tu-muenchen.de

S. Heres

Klinikum rechts der Isar, Klinik und Poliklinik für Psychiatrie und Psychotherapie, München, Germany

K. Lloyd

School of Medicine, University of Wales, Swansea, UK

E. Sacchetti

Clinica Psichiatrica, Spedali Civili di Brescia, Brescia, Italy

P. Bouhours

Janssen-Cilag, Medical Affairs Psychiatry, Issy-les-Moulineaux, France

R. Medori

Janssen-Cilag, Medical Affairs, EMEA, Beerse, Belgium

P. M. Llorca

Service Hospitalier Universitaire, Psychiatrie B, Clermont-Ferrand, France

This report presents data from the extension phase of a 6-month trial that evaluated the efficacy of risperidone long-acting injectable (RLAI) in stable psychotic patients requiring a treatment change.

Patients continued to receive RLAI every 2 weeks for a maximum of 12 months from study entry. Symptoms were assessed using the PANSS after 1, 3, 6, 9 and 12 months of treatment (or treatment endpoint). Remission of severity criteria were defined as 3 points in all PANSS items suggested by the Remission in Schizophrenia Working Group.

715 patients (63% male) entered the extension phase and 508 completed the 12-month study. The mean PANSS total score at Day 0 was 74.9±22.7. This was significantly reduced after 1 month (67.7 ±22.3, p0.001), with continued improvements over the 12 months of the study until treatment endpoint (59.7±21.9). Significant improvements from Day 0 to endpoint were also seen in the scores for all PANSS subscales and symptom factors. The proportion of patients who met the PANSS severity criteria for remission increased from 29% at Day 0 to 60% at endpoint, and the proportion of patients who met these criteria for 6 months increased from 24% at Month 6 to 45% at endpoint. Treatment with RLAI for up to 12 months provided significant and sustained improvements in symptom control in patients with schizophrenia. These improvements may help patients to achieve and remain in remission.

Key Words: risperidone • schizophrenia • long-acting • efficacy

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				A. M. Mortimer Symptom rating scales and outcome in schizophrenia The British Journal of Psychiatry, August 1, 2007; 191(50): s7 - s14. [Abstract] [Full Text] [PDF]

				H. A. Nasrallah and R. Lasser Improving patient outcomes in schizophrenia: achieving remission. J Psychopharmacol, November 1, 2006; 20(6 Suppl): 57 - 61. [Abstract] [PDF]